文献速递头颈部肿瘤放疗放疗物理与技术

更新版IVa区淋巴结勾画对鼻咽癌甲状腺剂量及甲减风险的影响

Impact of Updated Level IVa Nodal Delineation on Thyroid Dose and Hypothyroidism Risk in Nasopharyngeal Carcinoma.
PubMed 文献 · Adv Radiat Oncol · 2026-08-16

结果显示更新版勾画将甲状腺平均剂量从48.5 Gy降至44.8 Gy,甲减NTCP从43.9%降至34.9%,且不损害靶区覆盖。

要点

  • 甲减NTCP从43.9%降至34.9%,相对风险降低20.5%。
  • 靶区覆盖及其他危及器官剂量保持可比,支持广泛实施新指南。

核心结论

  • 采用2024/2025国际共识指南的IVa区勾画可显著降低甲状腺和喉部剂量而不损害靶区覆盖。
  • 该剂量降低转化为有临床意义的原发性甲减风险下降,支持广泛实施以改善鼻咽癌幸存者结局。

研究设计与样本

  • 每例患者生成两种基于不同CTVn定义的比较治疗计划:2018版指南(IVa区前界为胸锁乳突肌前缘)与2024/2025版指南(前界移至舌骨下带状肌后缘)。
  • 计划优化时在保持靶区覆盖等效的前提下最小化甲状腺和喉部剂量,采用配对分析比较剂量学参数及甲减与喉水肿的NTCP。

主要发现

  • 更新版CTVn勾画使甲状腺平均剂量从48.5 Gy降至44.8 Gy(P < .001)。
  • 甲状腺V50从59.9%降至46.3%(P < .001)。
  • 喉平均剂量从25.9 Gy降至21.7 Gy(P < .001)。
  • 甲减NTCP从43.9%降至34.9%(P < .001),相对风险降低20.5%。
  • 靶区覆盖及其他危及器官剂量在两种计划间保持可比。

关键数值与推荐

  • 2018版指南:IVa区 elective nodal volume 前界定于胸锁乳突肌前缘。
  • 2024/2025版指南:IVa区前界移至舌骨下带状肌后缘。
  • 甲状腺平均剂量48.5 Gy vs 44.8 Gy(P < .001);甲状腺V50 59.9% vs 46.3%(P < .001)。
  • 喉平均剂量25.9 Gy vs 21.7 Gy(P < .001);甲减NTCP 43.9% vs 34.9%(P < .001),相对风险降低20.5%。

临床怎么用

  • 鼻咽癌放疗勾画IVa区 elective nodal volume 时,应采用2024/2025国际共识指南将前界置于舌骨下带状肌后缘。
  • 该勾画调整可在不牺牲靶区覆盖的前提下降低甲状腺和喉部剂量,减少原发性甲减风险。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The 2024 and 2025 international consensus guidelines redefined the anterior border of the level IVa elective nodal volume for nasopharyngeal carcinoma (NPC). This study aimed to provide the first dosimetric validation of this anatomic refinement by quantifying its impact on thyroid and larynx doses and translating these reductions into clinically interpretable normal tissue complication probability (NTCP) estimates. METHODS AND MATERIALS: Thirty patients with NPC treated with helical tomotherapy were selected to represent a full spectrum of lower cervical nodal involvement. For each patient, 2 comparative treatment plans for different nodal clinical target volume (CTVn) definitions were generated: (1) CTVn based on 2018 guidelines, defining the level IVa anterior border at the anterior edge of the sternocleidomastoid muscle; and (2) CTVn based on 2024/2025 guidelines, shifting this border to the posterior edge of the infrahyoid ribbon muscles. Plans were optimized to minimize thyroid and larynx doses while maintaining equivalent target coverage. Dosimetric parameters and NTCP for hypothyroidism and laryngeal edema were compared using paired analyses. RESULTS: The updated CTVn delineation significantly reduced thyroid mean dose from 48.5 Gy to 44.8 Gy (P < .001) and thyroid volume receiving ≥50 Gy from 59.9% to 46.3% (P < .001). Larynx mean dose decreased from 25.9 Gy to 21.7 Gy (P < .001). The NTCP for hypothyroidism was reduced from 43.9% to 34.9% (P < .001), corresponding to a 20.5% relative risk reduction. Target coverage and doses to other organs at risk remained comparable between plans. CONCLUSIONS: Adopting the updated 2024/2025 international consensus guidelines for level IVa delineation significantly reduces radiation dose to the thyroid and larynx without compromising target coverage. This translates into a clinically meaningful reduction in the risk of primary hypothyroidism, supporting the widespread implementation of these guidelines to improve survivorship outcomes in patients with NPC.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Lui JCF, Lee VHF, Lee FKH, et al. Impact of Updated Level IVa Nodal Delineation on Thyroid Dose and Hypothyroidism Risk in Nasopharyngeal Carcinoma. Adv Radiat Oncol. 2026. PMID: 42824063. doi:10.1016/j.adro.2026.102178

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。